Partial
Partially Aligned
Patient Risk:
Low
Summary
Several non-label-specific regulatory/patent/reimbursement/general competition statements are not supported by the provided FDA label excerpts. Label-supported items about identity, oral dosing, and indication wording are otherwise broadly consistent with the supplied sections.
Category Scores
Accurate Statements
Xtandi is the brand name for enzalutamide.
XTANDI is the product name with active ingredient enzalutamide (Sections 1, 2, and multiple references in Sections 5-8 and 12).
Xtandi is an oral treatment.
Recommended dosage is administered orally once daily (Section 2.1).
Xtandi is used for certain stages of prostate cancer in the United States.
XTANDI indicated for CRPC, mCSPC, and nmCSPC with high-risk BCR (Section 1).
Enzalutamide has multiple U.S. approvals tied to different prostate cancer disease states.
XTANDI indicated for multiple disease states: CRPC, mCSPC, and nmCSPC with high-risk BCR (Section 1).
The U.S. indication/status of Xtandi depends on the current FDA indication/status.
The label excerpt provides specific FDA-approved indications (Section 1), but the claim is a general relationship and is not explicitly stated in the excerpt; treated as broadly consistent with the labeling concept.
Unsupported Statements
The U.S. regulatory status and availability of Xtandi depend on the specific prostate cancer setting being treated.
Not described in the provided labeling excerpts (no statements about regulatory status/availability varying by setting beyond listing indications).
U.S. approvals control how Xtandi can be prescribed and reimbursed in the U.S.
Label excerpts do not discuss reimbursement or prescribing control mechanisms (e.g., payer rules).
Patent expiration and any regulatory exclusivity extensions affect when Xtandi loses exclusivity/patent protection in the U.S.
No patent/exclusivity/patent-life content appears in the provided label excerpts.
Whether generic or biosimilar-like competition is possible depends on the specific patent(s) covering enzalutamide in each indication.
No discussion of generic/biosimilar competition or patent linkage is present in the provided label excerpts.
For small-molecule enzalutamide, generic entry is the key issue rather than biosimilars.
No labeling excerpt addresses biosimilars vs generics.
Whether a generic enzalutamide product is available in the U.S. depends on patent and exclusivity status for enzalutamide.
No discussion of generic availability, patent status, or regulatory exclusivity is present in the provided label excerpts.
Contradictions
Important Omissions
Specific labeled dosing details (160 mg once daily; with or without food; duration until disease progression or unacceptable toxicity) were not stated in the claims, beyond the general 'oral treatment' description.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety-relevant omissions are around dosing/administration specifics; however, none of the evaluated claims directly provide incorrect safety guidance. Unsupported regulatory/patent statements do not themselves instruct use, but they are not label-supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about regulatory status, reimbursement, patents/exclusivity, and generic/biosimilar competition are absent from the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported content: product identity (XTANDI/enzalutamide), oral dosing (Section 2.1), and FDA-approved indications (Section 1). Remove or qualify patent/exclusivity/generic/biosimilar/reimbursement assertions since they are not supported by the provided labeling.